News

The distributor agreement covers WaferGen’s entire family of SmartSlide Micro-Incubation System products. According to the company, WaferGen’s SmartSlide Micro-Incubation System is a first-of-its-kind family of integrated fluidics exchange

Regeneron was granted marketing approval for Arcalyst by the FDA in February 2008, making it the only therapy approved for patients with cryopyrin-associated periodic syndromes (CAPS), a group

Terms of the deal include upfront payments already made, future payments, R&D support as well as milestones for success for BioChemics (BCI). John Masiz, president & CEO of

In 69% of patients, the area treated with AN2728 scored better at the end of therapy than the area treated with the vehicle ointment, compared with six percent

The acquisition is a cash and stock transaction valued at $24 million, payable at closing, consisting of $7 million of cash and 2.2 million shares of Bio-Imaging stock

The multicenter, double-blind, placebo-controlled trial will evaluate the efficacy and safety of Adlea in reducing post-surgical pain in patients undergoing a bunionectomy procedure. The trial, to be conducted

The study is expected to be completed during the third quarter of 2008, with data available shortly thereafter. The results from this study will supplement the existing clinical

Orphan drug designation provides an important economic incentive for the development of new products in the cancer field. The US orphan drug designation provides for seven years of

Taro’s Ondansetron Injection is used for the prevention of nausea and vomiting associated with chemotherapy. This new Taro sterile injectable prescription product is bioequivalent to GlaxoSmithKline’s Zofran Injection,